Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.22B
EBITDA Margin
8.83%
TTM Avg
3.81%
3Y Avg
0.53%
5Y Avg
2.86%
Market Cap
$1.21B
EBITDA Margin
-2.25%
TTM Avg
-29.69%
3Y Avg
-65.15%
5Y Avg
-190.58%
Market Cap
$1.20B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.16B
EBITDA Margin
21.67%
TTM Avg
19.38%
3Y Avg
14.20%
5Y Avg
2.75%
Market Cap
$1.14B
EBITDA Margin
21.12%
TTM Avg
16.04%
3Y Avg
11.58%
5Y Avg
9.26%
Market Cap
$1.14B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.24B | N/A | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 8.83% | 3.81% | 0.53% | 2.86% |
| Cronos Group Inc. (CRON)vs › | $1.21B | -2.25% | -29.69% | -65.15% | -190.58% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 21.67% | 19.38% | 14.20% | 2.75% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.14B | 21.12% | 16.04% | 11.58% | 9.26% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.36B | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute